Total assets $ 6,740,140 $ 12,212,609
=========== ===========
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities:
Accounts payable $ 3,127,348 $ 1,359,898
Accrued expenses 934,372 1,152,460
Deferred underwriting commissions -- 2,911,260
Warrant liability 4,803 141,276
----------- -----------
Total current liabilities 4,066,523 5,564,894
----------- -----------
Total liabilities 4,066,523 5,564,894
----------- -----------
Stockholders' equity:
Common Stock, $0.001 par value;
500,000,000 shares authorized at
September 30, 2024 and December
31, 2023 and 4,292,455 and
264,537 issued and outstanding
at September 30, 2024 and
December 31, 2023, respectively 4,292 265
Additional paid-in-capital 41,449,244 32,114,552
Accumulated deficit (38,779,919) (25,467,102)
----------- -----------
Total stockholders' equity 2,673,617 6,647,715
----------- -----------
Total liabilities and stockholders'
equity $ 6,740,140 $ 12,212,609
=========== ===========
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108038521/en/
CONTACT: Chester Zygmont, III
Chief Financial Officer
Email: czygmont@revbiosciences.com
(END) Dow Jones Newswires
November 08, 2024 16:15 ET (21:15 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。